Literature DB >> 27515050

Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.

Byung-Hak Kim1,2, Eun Hee Yi1,3, Sang-Kyu Ye4,5,6,7.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of a variety of genes to regulate important biological functions, including cell proliferation, differentiation, survival, angiogenesis, and immune response. Constitutive activation of STAT3 is important in oncogenic signaling and occurs at high frequency in human cancers, including diverse solid tumors and hematologic malignancies. Moreover, it is associated with a poor prognosis. The tumor microenvironment has recently been recognized as a key condition for cancer progression, invasion, angiogenesis, metastasis, and drug resistance by activation of STAT3 signaling. Therefore, understanding the biology associated with STAT3-mediated signaling cascades in the tumor microenvironment may offer the therapeutic potential to treat human cancers. This review presents an overview of the critical roles of STAT3 in the tumor microenvironment related to cancer biology and discusses recent advancements in the development of anticancer drugs that therapeutically inhibit STAT3 signaling cascades.

Entities:  

Keywords:  Cancer; Inflammation; Signal transducer and activator of transcription 3 (STAT3); Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27515050     DOI: 10.1007/s12272-016-0795-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  31 in total

Review 1.  Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.

Authors:  Nikolas Balanis; Cathleen R Carlin
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

2.  miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.

Authors:  Liang Xia; Linlin Wu; Hailong Xia; Jing Bao; Qingsheng Li; Xiaowen Chen; Ruixiang Xia
Journal:  Cell Cycle       Date:  2019-06-18       Impact factor: 4.534

3.  Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.

Authors:  Dingyuan Luo; Magdalena Fraga-Lauhirat; Jonathan Millings; Cristella Ho; Emily M Villarreal; Teresa C Fletchinger; James V Bonfiglio; Leyda Mata; Matthew D Nemesure; Lauren E Bartels; Ruixue Wang; Basil Rigas; Gerardo G Mackenzie
Journal:  Carcinogenesis       Date:  2019-12-31       Impact factor: 4.944

4.  STAT3 mediates RCP-induced cancer cell invasion through the NF-κB/Slug/MT1-MMP signaling cascade.

Authors:  Su Jin Cho; Bo Young Jeong; Young Soo Song; Chang Gyo Park; Do Yeun Cho; Hoi Young Lee
Journal:  Arch Pharm Res       Date:  2022-07-09       Impact factor: 6.010

5.  Investigating the potential therapeutic role of targeting STAT3 for overcoming drug resistance by regulating energy metabolism in chronic myeloid leukemia cells.

Authors:  Burcin Tezcanli Kaymaz; Nur Selvi Gunel; Fatma Sogutlu; Neslihan Pinar Ozates Ay; Yusuf Baran; Cumhur Gunduz; Cigir Biray Avci
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

Review 6.  The potential role of leptin in tumor invasion and metastasis.

Authors:  Amitabha Ray; Margot P Cleary
Journal:  Cytokine Growth Factor Rev       Date:  2017-11-11       Impact factor: 7.638

7.  ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma.

Authors:  Xuemei Ding; Jian Kong; Wenlei Xu; Shuying Dong; Yingrui Du; Changyu Yao; Jun Gao; Shan Ke; Shaohong Wang; Wenbing Sun
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

8.  A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer.

Authors:  Wen Chen; Wenrong He; Hongbing Cai; Bicheng Hu; Caishang Zheng; Xianliang Ke; Li Xie; Zhenhua Zheng; Xinxing Wu; Hanzhong Wang
Journal:  Oncotarget       Date:  2017-06-13

9.  Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.

Authors:  Xiaohui Xie; Mengyuan Yang; Yiling Ding; Ling Yu; Jianlin Chen
Journal:  Oncol Rep       Date:  2017-10-13       Impact factor: 3.906

10.  Combination curcumin and (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway.

Authors:  G Jin; Y Yang; K Liu; J Zhao; X Chen; H Liu; R Bai; X Li; Y Jiang; X Zhang; J Lu; Z Dong
Journal:  Oncogenesis       Date:  2017-10-02       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.